Table 4.

RR (95% CI) for the association between GSTM1, GSTT1, and NAT2 genotype and epithelial ovarian cancer risk in the NECC and the NHS

NECC*
NHS*
Pooled
Cases (%)Controls (%)RR (95% CI)Cases (%)Controls (%)RR (95% CI)RR (95% CI)
N1,1751,202210600
GSTM1 genotype
    Present573 (49.1)567 (47.4)1.00 (reference)102 (52.3)268 (48.5)1.00 (reference)1.00 (reference)
    Null594 (50.9)628 (52.6)0.93 (0.79-1.10)93 (47.7)285 (51.5)0.83 (0.58-1.17)0.91 (0.78-1.06)
GSTT1 genotype
    Present919 (78.8)938 (78.5)1.00 (reference)157 (81.3)439 (78.8)1.00 (reference)1.00 (reference)
    Null247 (21.2)257 (21.5)0.98 (0.80-1.21)36 (18.7)118 (21.2)0.87 (0.57-1.33)0.96 (0.80-1.16)
NAT2 genotype
    Rapid/intermediate acetylator387 (36.8)405 (36.1)1.00 (reference)77 (41.0)182 (33.0)1.00 (reference)1.00 (reference)
    Slow acetylator665 (63.2)717 (63.9)0.97 (0.81-1.15)111 (59.0)369 (67.0)0.65 (0.45-0.95)0.82 (0.57-1.20)
Combined GSTM1/GSTT1 genotype
    Both present445 (38.2)430 (36.0)1.00 (reference)81 (44.3)206 (39.2)1.00 (reference)1.00 (reference)
    M1 null, T1 present474 (40.7)508 (42.5)0.91 (0.76-1.10)68 (37.2)208 (39.5)0.82 (0.54-1.22)0.89 (0.75-1.06)
    M1 present, T1 null128 (11.0)137 (11.5)0.94 (0.71-1.24)17 (9.3)49 (9.3)0.98 (0.52-1.84)0.94 (0.73-1.22)
    Both null119 (10.2)120 (10.0)0.94 (0.70-1.26)17 (9.3)63 (12.0)0.65 (0.34-1.24)0.88 (0.67-1.15)
Combined GSTM1/NAT2 genotype
    GSTM1 present, NAT2 rapid195 (18.6)188 (16.9)1.00 (reference)37 (21.0)85 (16.4)1.00 (reference)1.00 (reference)
    GSTM1 null, NAT2 rapid189 (18.1)214 (19.2)0.82 (0.61-1.09)35 (19.9)91 (17.5)0.96 (0.53-1.74)0.84 (0.65-1.09)
    GSTM1 present, NAT2 slow315 (30.1)343 (30.7)0.86 (0.66-1.11)56 (31.8)161 (31.0)0.87 (0.51-1.50)0.86 (0.68-1.09)
    GSTM1 null, NAT2 slow347 (33.2)371 (33.2)0.88 (0.68-1.14)48 (27.3)183 (35.2)0.57 (0.33-0.98)0.76 (0.50-1.14)
Combined GSTT1/NAT2 genotype
    GSTT1 present, NAT2 rapid296 (28.3)312 (28.0)1.00 (reference)52 (29.7)144 (27.5)1.00 (reference)1.00 (reference)
    GSTT1 null, NAT2 rapid88 (8.4)90 (8.1)1.03 (0.73-1.45)17 (9.7)30 (5.7)1.55 (0.76-3.16)1.11 (0.81-1.52)
    GSTT1 present, NAT2 slow519 (49.7)562 (50.4)0.97 (0.79-1.19)90 (51.4)270 (51.6)0.87 (0.57-1.33)0.95 (0.79-1.14)
    GSTT1 null, NAT2 slow142 (13.6)152 (13.6)0.98 (0.74-1.31)16 (9.1)79 (15.1)0.51 (0.26-0.99)0.76 (0.40-1.43)
  • * Unconditional (NECC) and conditional (NHS) logistic regression adjusted for age, study center (NECC only), duration of oral contraceptive use (months), parity (continuous), tubal ligation, BMI (kg/m2, continuous), and duration of PMH use (months).

  • P values for tests for heterogeneity comparing the NECC and NHS results were all >0.06.

  • Frequencies do not add up to total N due to missing genotype data.